These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11451210)

  • 1. Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist.
    Brunner HR; Nussberger J
    J Hypertens Suppl; 2001 Jun; 19(1):S15-20. PubMed ID: 11451210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients.
    Püchler K; Nussberger J; Laeis P; Witte PU; Brunner HR
    J Hypertens; 1997 Dec; 15(12 Pt 2):1809-12. PubMed ID: 9488244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview.
    Brunner HR
    J Hum Hypertens; 2002 May; 16 Suppl 2():S13-6. PubMed ID: 11967728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy and tolerability of olmesartan.
    Brunner HR
    Clin Ther; 2004; 26 Suppl A():A28-32. PubMed ID: 15291377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olmesartan medoxomil: the seventh angiotensin receptor antagonist.
    Gardner SF; Franks AM
    Ann Pharmacother; 2003 Jan; 37(1):99-105. PubMed ID: 12503943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonizing the angiotensin II subtype 1 receptor: a focus on olmesartan medoxomil.
    Nussberger J; Koike H
    Clin Ther; 2004; 26 Suppl A():A12-20. PubMed ID: 15291375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
    Smith DH; Dubiel R; Jones M
    Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake.
    Jones MR; Sealey JE; Laragh JH
    Am J Hypertens; 2007 Aug; 20(8):907-16. PubMed ID: 17679042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension.
    Hazan L; Hernández Rodriguez OA; Bhorat AE; Miyazaki K; Tao B; Heyrman R;
    Hypertension; 2010 Jun; 55(6):1323-30. PubMed ID: 20385971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of effects of angiotensin II receptor blocker on morning home blood pressure and cardiorenal protection between morning administration and evening administration in hypertensive patients: the COMPATIBLE study.
    Mori H; Yamamoto H; Ukai H; Yuasa S; Nakajima K; Mikawa T; Niizuma M; Hirao K; Umemura S;
    Hypertens Res; 2013 Mar; 36(3):202-7. PubMed ID: 23013888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension.
    Chrysant SG; Marbury TC; Robinson TD
    J Hum Hypertens; 2003 Jun; 17(6):425-32. PubMed ID: 12764406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
    Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
    Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olmesartan medoxomil.
    Warner GT; Jarvis B
    Drugs; 2002; 62(9):1345-53; discussion 1354-6. PubMed ID: 12076183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients.
    Ichikawa S; Takayama Y
    Hypertens Res; 2001 Nov; 24(6):641-6. PubMed ID: 11768722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between the frequency of blood pressure self-measurement and blood pressure reduction with antihypertensive therapy : results of the OLMETEL (OLMEsartan TELemonitoring blood pressure) study.
    Ewald S; vor dem Esche J; Uen S; Neikes F; Vetter H; Mengden T
    Clin Drug Investig; 2006; 26(8):439-46. PubMed ID: 17163276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements.
    Neutel J; Elliott WJ; Izzo J; Chen CL; Masonson H
    J Clin Hypertens (Greenwich); 2002; 4(5):325-31. PubMed ID: 12368570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes.
    Mizuno M; Sada T; Kato M; Koike H
    Hypertens Res; 2002 Mar; 25(2):271-8. PubMed ID: 12047043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olmesartan medoxomil: an angiotensin II-receptor blocker.
    Brousil JA; Burke JM
    Clin Ther; 2003 Apr; 25(4):1041-55. PubMed ID: 12809956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study.
    Kereiakes DJ; Maa JF; Shojaee A; Dubiel R
    Am J Cardiovasc Drugs; 2010; 10(4):239-46. PubMed ID: 20653330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide.
    Chrysant SG; Weber MA; Wang AC; Hinman DJ
    Am J Hypertens; 2004 Mar; 17(3):252-9. PubMed ID: 15001200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.